<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" dtd-version="1.0" article-type="reference-list">
<front>
<article-meta>
<custom-meta-group>
<custom-meta><meta-name>TotalReferences</meta-name><meta-value>26</meta-value></custom-meta>
<custom-meta><meta-name>ReferencesParsed</meta-name><meta-value>23</meta-value></custom-meta>
<custom-meta><meta-name>ReferencesBillable</meta-name><meta-value>22</meta-value></custom-meta>
<custom-meta><meta-name>LinkServices</meta-name><meta-value>pubmed-crossref</meta-value></custom-meta>
<custom-meta><meta-name>ReferencesLinked</meta-name><meta-value>23</meta-value></custom-meta>
<custom-meta><meta-name>ReferencesLinkedDOI</meta-name><meta-value>22</meta-value></custom-meta>
<custom-meta><meta-name>ReferencesLinkedPMID</meta-name><meta-value>23</meta-value></custom-meta>
<custom-meta><meta-name>JournalReferences</meta-name><meta-value>23</meta-value></custom-meta>
<custom-meta><meta-name>BookReferences</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>BookChapterReferences</meta-name><meta-value>1</meta-value></custom-meta>
<custom-meta><meta-name>ConferenceReferences</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>ElectronicReferences</meta-name><meta-value>1</meta-value></custom-meta>
<custom-meta><meta-name>DissertationReferences</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>LegalReferences</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>StandardReferences</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>OtherReferences</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>UnknownReferences</meta-name><meta-value>1</meta-value></custom-meta>
<custom-meta><meta-name>ReferencesSemiParsed</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>ReferencesBookUnparsed</meta-name><meta-value>1</meta-value></custom-meta>
<custom-meta><meta-name>EditorialStyle</meta-name><meta-value>ICMJE-WHO</meta-value></custom-meta>
</custom-meta-group>
</article-meta>
</front>
<back>
<ref-list>
<ref id="b1"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Vallianou</surname> <given-names>NG</given-names></string-name>, <string-name><surname>Geladari</surname> <given-names>E</given-names></string-name>, <string-name><surname>Kazazis</surname> <given-names>CE</given-names></string-name></person-group>. <article-title>SGLT-2 inhibitors: their pleiotropic properties</article-title>. <source>Diabetes Metab Syndr</source>. <year>2017</year> <month>Oct - Dec</month>;<volume>11</volume>(<issue>4</issue>):<fpage>311</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.dsx.2016.12.003</pub-id><pub-id pub-id-type="pmid">28011230</pub-id><issn>1871-4021</issn></mixed-citation></ref>
<ref id="b2"><mixed-citation publication-type="web-page" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Diabetes Atlas</surname> <given-names>ID</given-names></string-name></person-group>. - 8th Edition <year>2017</year> [Available from: <ext-link ext-link-type="uri" xlink:href="http://www.diabetesatlas.org/#">http://www.diabetesatlas.org/#</ext-link></mixed-citation></ref>
<ref id="b3"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Storgaard</surname> <given-names>H</given-names></string-name>, <string-name><surname>Gluud</surname> <given-names>LL</given-names></string-name>, <string-name><surname>Bennett</surname> <given-names>C</given-names></string-name>, <string-name><surname>Grøndahl</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Christensen</surname> <given-names>MB</given-names></string-name>, <string-name><surname>Knop</surname> <given-names>FK</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis</article-title>. <source>PLoS One</source>. <year>2016</year> <month>Nov</month>;<volume>11</volume>(<issue>11</issue>):<fpage>e0166125</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0166125</pub-id><pub-id pub-id-type="pmid">27835680</pub-id><issn>1932-6203</issn></mixed-citation></ref>
<ref id="b4"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Ivo-Dos-Santos</surname> <given-names>J</given-names></string-name>, <string-name><surname>Campos</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Galvão-Castro</surname> <given-names>B</given-names></string-name></person-group>. <article-title>Patterns of serologic response to human immunodeficiency virus type 1 (HIV-1) in Brazilians with different clinical forms of HIV infection</article-title>. <source>Mem Inst Oswaldo Cruz</source>. <year>1989</year> <month>Jan-Mar</month>;<volume>84</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1590/S0074-02761989000100003</pub-id><pub-id pub-id-type="pmid">2319954</pub-id><issn>0074-0276</issn></mixed-citation></ref>
<ref id="b5"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Kalra</surname> <given-names>S</given-names></string-name>, <string-name><surname>Singh</surname> <given-names>V</given-names></string-name>, <string-name><surname>Nagrale</surname> <given-names>D</given-names></string-name></person-group>. <article-title>Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review</article-title>. <source>Adv Ther</source>. <year>2016</year> <month>Sep</month>;<volume>33</volume>(<issue>9</issue>):<fpage>1502</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1007/s12325-016-0379-5</pub-id><pub-id pub-id-type="pmid">27423646</pub-id><issn>0741-238X</issn></mixed-citation></ref>
<ref id="b6"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Kalra</surname> <given-names>S</given-names></string-name></person-group>. <article-title>Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology</article-title>. <source>Diabetes Ther</source>. <year>2014</year> <month>Dec</month>;<volume>5</volume>(<issue>2</issue>):<fpage>355</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1007/s13300-014-0089-4</pub-id><pub-id pub-id-type="pmid">25424969</pub-id><issn>1869-6953</issn></mixed-citation></ref>
<ref id="b7"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Lioudaki</surname> <given-names>E</given-names></string-name>, <string-name><surname>Androulakis</surname> <given-names>ES</given-names></string-name>, <string-name><surname>Whyte</surname> <given-names>M</given-names></string-name>, <string-name><surname>Stylianou</surname> <given-names>KG</given-names></string-name>, <string-name><surname>Daphnis</surname> <given-names>EK</given-names></string-name>, <string-name><surname>Ganotakis</surname> <given-names>ES</given-names></string-name></person-group>. <article-title>The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action</article-title>. <source>Cardiovasc Drugs Ther</source>. <year>2017</year> <month>Apr</month>;<volume>31</volume>(<issue>2</issue>):<fpage>215</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1007/s10557-017-6724-3</pub-id><pub-id pub-id-type="pmid">28444472</pub-id><issn>0920-3206</issn></mixed-citation></ref>
<ref id="b8"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Martens</surname> <given-names>P</given-names></string-name>, <string-name><surname>Mathieu</surname> <given-names>C</given-names></string-name>, <string-name><surname>Verbrugge</surname> <given-names>FH</given-names></string-name></person-group>. <article-title>Promise of SGLT2 Inhibitors in Heart Failure: diabetes and Beyond</article-title>. <source>Curr Treat Options Cardiovasc Med</source>. <year>2017</year> <month>Mar</month>;<volume>19</volume>(<issue>3</issue>):<fpage>23</fpage>. <pub-id pub-id-type="doi">10.1007/s11936-017-0522-x</pub-id><pub-id pub-id-type="pmid">28299616</pub-id><issn>1092-8464</issn></mixed-citation></ref>
<ref id="b9"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Zinman</surname> <given-names>B</given-names></string-name>, <string-name><surname>Lachin</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Inzucchi</surname> <given-names>SE</given-names></string-name></person-group>. <article-title>Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes</article-title>. <source>N Engl J Med</source>. <year>2016</year> <month>Mar</month>;<volume>374</volume>(<issue>11</issue>):<fpage>1094</fpage>.<pub-id pub-id-type="pmid">26981940</pub-id><issn>1533-4406</issn></mixed-citation></ref>
<ref id="b10"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Farahani</surname> <given-names>P</given-names></string-name></person-group>. <article-title>Non-severe Hypoglycemia Risk Difference between Sulfonylurea and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2-I) as an Add-On to Metformin in Randomized Controlled Trials</article-title>. <source>J Popul Ther Clin Pharmacol</source>. <year>2017</year> <month>May</month>;<volume>24</volume>(<issue>2</issue>):<fpage>e32</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.22374/1710-6222.24.2.6</pub-id><pub-id pub-id-type="pmid">28594482</pub-id><issn>1710-6222</issn></mixed-citation></ref>
<ref id="b11"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Cai</surname> <given-names>X</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>X</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis</article-title>. <source>Obesity (Silver Spring)</source>. <year>2018</year> <month>Jan</month>;<volume>26</volume>(<issue>1</issue>):<fpage>70</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1002/oby.22066</pub-id><pub-id pub-id-type="pmid">29165885</pub-id><issn>1930-7381</issn></mixed-citation></ref>
<ref id="b12"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Ahmadieh</surname> <given-names>H</given-names></string-name>, <string-name><surname>Azar</surname> <given-names>S</given-names></string-name></person-group>. <article-title>Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus</article-title>. <source>Diabetes Technol Ther</source>. <year>2017</year> <month>Sep</month>;<volume>19</volume>(<issue>9</issue>):<fpage>507</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1089/dia.2017.0070</pub-id><pub-id pub-id-type="pmid">28749169</pub-id><issn>1520-9156</issn></mixed-citation></ref>
<ref id="b13"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Shyangdan</surname> <given-names>DS</given-names></string-name>, <string-name><surname>Uthman</surname> <given-names>OA</given-names></string-name>, <string-name><surname>Waugh</surname> <given-names>N</given-names></string-name></person-group>. <article-title>SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis</article-title>. <source>BMJ Open</source>. <year>2016</year> <month>Feb</month>;<volume>6</volume>(<issue>2</issue>):<fpage>e009417</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2015-009417</pub-id><pub-id pub-id-type="pmid">26911584</pub-id><issn>2044-6055</issn></mixed-citation></ref>
<ref id="b14"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Cherney</surname> <given-names>DZ</given-names></string-name>, <string-name><surname>Perkins</surname> <given-names>BA</given-names></string-name>, <string-name><surname>Soleymanlou</surname> <given-names>N</given-names></string-name>, <string-name><surname>Har</surname> <given-names>R</given-names></string-name>, <string-name><surname>Fagan</surname> <given-names>N</given-names></string-name>, <string-name><surname>Johansen</surname> <given-names>OE</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus</article-title>. <source>Cardiovasc Diabetol</source>. <year>2014</year> <month>Jan</month>;<volume>13</volume>(<issue>1</issue>):<fpage>28</fpage>. <pub-id pub-id-type="doi">10.1186/1475-2840-13-28</pub-id><pub-id pub-id-type="pmid">24475922</pub-id><issn>1475-2840</issn></mixed-citation></ref>
<ref id="b15"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Fioretto</surname> <given-names>P</given-names></string-name>, <string-name><surname>Zambon</surname> <given-names>A</given-names></string-name>, <string-name><surname>Rossato</surname> <given-names>M</given-names></string-name>, <string-name><surname>Busetto</surname> <given-names>L</given-names></string-name>, <string-name><surname>Vettor</surname> <given-names>R</given-names></string-name></person-group>. <article-title>SGLT2 Inhibitors and the Diabetic Kidney</article-title>. <source>Diabetes Care</source>. <year>2016</year> <month>Aug</month>;<volume>39</volume> <supplement>Suppl 2</supplement>:<fpage>S165</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.2337/dcS15-3006</pub-id><pub-id pub-id-type="pmid">27440829</pub-id><issn>0149-5992</issn></mixed-citation></ref>
<ref id="b16"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Perrone-Filardi</surname> <given-names>P</given-names></string-name>, <string-name><surname>Avogaro</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bonora</surname> <given-names>E</given-names></string-name>, <string-name><surname>Colivicchi</surname> <given-names>F</given-names></string-name>, <string-name><surname>Fioretto</surname> <given-names>P</given-names></string-name>, <string-name><surname>Maggioni</surname> <given-names>AP</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Mechanisms linking empagliflozin to cardiovascular and renal protection</article-title>. <source>Int J Cardiol</source>. <year>2017</year> <month>Aug</month>;<volume>241</volume>:<fpage>450</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2017.03.089</pub-id><pub-id pub-id-type="pmid">28395981</pub-id><issn>0167-5273</issn></mixed-citation></ref>
<ref id="b17"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Rastogi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bhansali</surname> <given-names>A</given-names></string-name></person-group>. <article-title>SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review</article-title>. <source>Diabetes Ther</source>. <year>2017</year> <month>Dec</month>;<volume>8</volume>(<issue>6</issue>):<fpage>1245</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1007/s13300-017-0320-1</pub-id><pub-id pub-id-type="pmid">29076040</pub-id><issn>1869-6953</issn></mixed-citation></ref>
<ref id="b18"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Zinman</surname> <given-names>B</given-names></string-name>, <string-name><surname>Wanner</surname> <given-names>C</given-names></string-name>, <string-name><surname>Lachin</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Fitchett</surname> <given-names>D</given-names></string-name>, <string-name><surname>Bluhmki</surname> <given-names>E</given-names></string-name>, <string-name><surname>Hantel</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal>; <collab>EMPA-REG OUTCOME Investigators</collab></person-group>. <article-title>Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes</article-title>. <source>N Engl J Med</source>. <year>2015</year> <month>Nov</month>;<volume>373</volume>(<issue>22</issue>):<fpage>2117</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1504720</pub-id><pub-id pub-id-type="pmid">26378978</pub-id><issn>0028-4793</issn></mixed-citation></ref>
<ref id="b19"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Neal</surname> <given-names>B</given-names></string-name>, <string-name><surname>Perkovic</surname> <given-names>V</given-names></string-name>, <string-name><surname>Mahaffey</surname> <given-names>KW</given-names></string-name>, <string-name><surname>de Zeeuw</surname> <given-names>D</given-names></string-name>, <string-name><surname>Fulcher</surname> <given-names>G</given-names></string-name>, <string-name><surname>Erondu</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal>; <collab>CANVAS Program Collaborative Group</collab></person-group>. <article-title>Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes</article-title>. <source>N Engl J Med</source>. <year>2017</year> <month>Aug</month>;<volume>377</volume>(<issue>7</issue>):<fpage>644</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1611925</pub-id><pub-id pub-id-type="pmid">28605608</pub-id><issn>0028-4793</issn></mixed-citation></ref>
<ref id="b20"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Filippatos</surname> <given-names>TD</given-names></string-name>, <string-name><surname>Tsimihodimos</surname> <given-names>V</given-names></string-name>, <string-name><surname>Liamis</surname> <given-names>G</given-names></string-name>, <string-name><surname>Elisaf</surname> <given-names>MS</given-names></string-name></person-group>. <article-title>SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms</article-title>. <source>Diabetes Metab Syndr</source>. <year>2018</year> <month>Jan - Mar</month>;<volume>12</volume>(<issue>1</issue>):<fpage>59</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.dsx.2017.08.003</pub-id><pub-id pub-id-type="pmid">28826578</pub-id><issn>1871-4021</issn></mixed-citation></ref>
<ref id="b21"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Lytvyn</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Bjornstad</surname> <given-names>P</given-names></string-name>, <string-name><surname>Udell</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Lovshin</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Cherney</surname> <given-names>DZ</given-names></string-name></person-group>. <article-title>Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials</article-title>. <source>Circulation</source>. <year>2017</year> <month>Oct</month>;<volume>136</volume>(<issue>17</issue>):<fpage>1643</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.030012</pub-id><pub-id pub-id-type="pmid">29061576</pub-id><issn>0009-7322</issn></mixed-citation></ref>
<ref id="b22"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Rosenstock</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ferrannini</surname> <given-names>E</given-names></string-name></person-group>. <article-title>Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors</article-title>. <source>Diabetes Care</source>. <year>2015</year> <month>Sep</month>;<volume>38</volume>(<issue>9</issue>):<fpage>1638</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.2337/dc15-1380</pub-id><pub-id pub-id-type="pmid">26294774</pub-id><issn>0149-5992</issn></mixed-citation></ref>
<ref id="b23"><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Goldenberg</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Berard</surname> <given-names>LD</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>AY</given-names></string-name>, <string-name><surname>Gilbert</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Verma</surname> <given-names>S</given-names></string-name>, <string-name><surname>Woo</surname> <given-names>VC</given-names></string-name>, <etal>et al.</etal></person-group> SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis. Clin Ther. <year>2016</year>;38(12):2654–64 e1.</mixed-citation></ref>
<ref id="b24"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Handelsman</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Henry</surname> <given-names>RR</given-names></string-name>, <string-name><surname>Bloomgarden</surname> <given-names>ZT</given-names></string-name>, <string-name><surname>Dagogo-Jack</surname> <given-names>S</given-names></string-name>, <string-name><surname>DeFronzo</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Einhorn</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of Sglt-2 Inhibitors and Diabetic Ketoacidosis</article-title>. <source>Endocr Pract</source>. <year>2016</year> <month>Jun</month>;<volume>22</volume>(<issue>6</issue>):<fpage>753</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.4158/EP161292.PS</pub-id><pub-id pub-id-type="pmid">27082665</pub-id><issn>1530-891X</issn></mixed-citation></ref>
<ref id="b25"><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Scheen</surname> <given-names>AJ</given-names></string-name></person-group>. <article-title>Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus</article-title>. <source>Drugs</source>. <year>2015</year> <month>Jan</month>;<volume>75</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1007/s40265-014-0337-y</pub-id><pub-id pub-id-type="pmid">25488697</pub-id><issn>0012-6667</issn></mixed-citation></ref>
<ref id="b26"><mixed-citation publication-type="book-chapter" specific-use="unparsed"><person-group person-group-type="editor"><string-name><surname>Zaletel</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ravnik Oblak</surname> <given-names>M</given-names></string-name>, <role>editors</role></person-group>. Slovenske smernice za klinično obravnavo sladkorne bolezni tipa 2. 3 ed. Ljubljana: Klinični oddelek za endokrinologijo, diabetes in presnovne bolezni, Interna klinika UKC Ljubljana in Klinični oddelek za endokrinologijo, diabetes in bolezni presnove, Pediatrična klinika Ljubljana; <year>2016</year>.</mixed-citation></ref>
</ref-list>
</back>
</article>
